Living	O
on	O
the	O
edge	O
:	O
substrate	O
competition	O
explains	O
loss	O
of	O
robustness	O
in	O
mitochondrial	B:C0026237
fatty	O
-	I:C1456270
acid	I:C1456270
oxidation	I:C1456270
disorders	I:C1456270
.	O

Living	O
on	O
the	O
edge	O
:	O
substrate	O
competition	O
explains	O
loss	O
of	O
robustness	O
in	O
mitochondrial	O
fatty	B:C1456270
-	I:C1456270
acid	I:C1456270
oxidation	I:C1456270
disorders	I:C1456270
.	O

Defects	O
in	O
genes	B:C0017337
involved	O
in	O
mitochondrial	O
fatty	O
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
(	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
)	O
reduce	O
the	O
ability	O
of	O
patients	O
to	O
cope	O
with	O
metabolic	O
challenges	O
.	O

Defects	O
in	O
genes	O
involved	O
in	O
mitochondrial	B:C0026237
fatty	O
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
(	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
)	O
reduce	O
the	O
ability	O
of	O
patients	O
to	O
cope	O
with	O
metabolic	O
challenges	O
.	O

Defects	O
in	O
genes	O
involved	O
in	O
mitochondrial	O
fatty	B:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
(	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
)	O
reduce	O
the	O
ability	O
of	O
patients	O
to	O
cope	O
with	O
metabolic	O
challenges	O
.	O

Defects	O
in	O
genes	O
involved	O
in	O
mitochondrial	O
fatty	O
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
(	O
mitochondrial	B:C1158366
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
)	O
reduce	O
the	O
ability	O
of	O
patients	O
to	O
cope	O
with	O
metabolic	O
challenges	O
.	O

mitochondrial	B:C1158366
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
enzymes	O
accept	O
multiple	O
substrates	O
of	O
different	O
chain	O
length	O
,	O
leading	O
to	O
molecular	O
competition	O
among	O
the	O
substrates	O
.	O

mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
enzymes	B:C0014442
accept	O
multiple	O
substrates	O
of	O
different	O
chain	O
length	O
,	O
leading	O
to	O
molecular	O
competition	O
among	O
the	O
substrates	O
.	O

Here	O
,	O
we	O
combined	O
computational	O
modeling	O
with	O
quantitative	O
mouse	B:C0026809
and	O
patient	O
data	O
to	O
investigate	O
whether	O
substrate	O
competition	O
affects	O
pathway	O
robustness	O
in	O
mFAO	O
disorders	I:C1456270
.	O

Here	O
,	O
we	O
combined	O
computational	O
modeling	O
with	O
quantitative	O
mouse	O
and	O
patient	O
data	O
to	O
investigate	O
whether	O
substrate	O
competition	O
affects	O
pathway	O
robustness	O
in	O
mFAO	B:C1456270
disorders	I:C1456270
.	O

First	O
,	O
we	O
used	O
comprehensive	O
biochemical	O
analyses	B:C0936012
of	O
wild	O
-	I:C1883559
type	I:C1883559
mice	O
and	O
mice	O
deficient	I:C0206745
for	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
(	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
)	O
to	O
parameterize	O
a	O
detailed	O
computational	O
model	I:C3161035
of	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
.	O

First	O
,	O
we	O
used	O
comprehensive	O
biochemical	O
analyses	O
of	O
wild	B:C1883559
-	I:C1883559
type	I:C1883559
mice	O
and	O
mice	O
deficient	I:C0206745
for	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
(	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
)	O
to	O
parameterize	O
a	O
detailed	O
computational	O
model	I:C3161035
of	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
.	O

First	O
,	O
we	O
used	O
comprehensive	O
biochemical	O
analyses	O
of	O
wild	O
-	I:C1883559
type	I:C1883559
mice	B:C0025929
and	O
mice	O
deficient	I:C0206745
for	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
(	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
)	O
to	O
parameterize	O
a	O
detailed	O
computational	O
model	I:C3161035
of	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
.	O

First	O
,	O
we	O
used	O
comprehensive	O
biochemical	O
analyses	O
of	O
wild	O
-	I:C1883559
type	I:C1883559
mice	O
and	O
mice	B:C0206745
deficient	I:C0206745
for	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
(	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
)	O
to	O
parameterize	O
a	O
detailed	O
computational	O
model	I:C3161035
of	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
.	O

First	O
,	O
we	O
used	O
comprehensive	O
biochemical	O
analyses	O
of	O
wild	O
-	I:C1883559
type	I:C1883559
mice	O
and	O
mice	O
deficient	I:C0206745
for	O
medium	B:C0050688
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
(	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
)	O
to	O
parameterize	O
a	O
detailed	O
computational	O
model	I:C3161035
of	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
.	O

First	O
,	O
we	O
used	O
comprehensive	O
biochemical	O
analyses	O
of	O
wild	O
-	I:C1883559
type	I:C1883559
mice	O
and	O
mice	O
deficient	I:C0206745
for	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
(	O
medium	B:C0050688
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
)	O
to	O
parameterize	O
a	O
detailed	O
computational	O
model	I:C3161035
of	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
.	O

First	O
,	O
we	O
used	O
comprehensive	O
biochemical	O
analyses	O
of	O
wild	O
-	I:C1883559
type	I:C1883559
mice	O
and	O
mice	O
deficient	I:C0206745
for	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
(	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
)	O
to	O
parameterize	O
a	O
detailed	O
computational	B:C3161035
model	I:C3161035
of	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
.	O

First	O
,	O
we	O
used	O
comprehensive	O
biochemical	O
analyses	O
of	O
wild	O
-	I:C1883559
type	I:C1883559
mice	O
and	O
mice	O
deficient	I:C0206745
for	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
(	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
)	O
to	O
parameterize	O
a	O
detailed	O
computational	O
model	I:C3161035
of	O
mitochondrial	B:C1158366
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
.	O

Model	B:C3161035
simulations	O
predicted	O
that	O
MCAD	O
deficiency	I:C0220710
would	O
have	O
no	O
effect	O
on	O
the	O
pathway	O
flux	O
at	O
low	O
concentrations	O
of	O
the	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
substrate	O
palmitoyl	O
-	I:C0030239
CoA	I:C0030239
.	O

Model	O
simulations	B:C0679083
predicted	O
that	O
MCAD	O
deficiency	I:C0220710
would	O
have	O
no	O
effect	O
on	O
the	O
pathway	O
flux	O
at	O
low	O
concentrations	O
of	O
the	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
substrate	O
palmitoyl	O
-	I:C0030239
CoA	I:C0030239
.	O

Model	O
simulations	O
predicted	O
that	O
MCAD	B:C0220710
deficiency	I:C0220710
would	O
have	O
no	O
effect	O
on	O
the	O
pathway	O
flux	O
at	O
low	O
concentrations	O
of	O
the	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
substrate	O
palmitoyl	O
-	I:C0030239
CoA	I:C0030239
.	O

Model	O
simulations	O
predicted	O
that	O
MCAD	O
deficiency	I:C0220710
would	O
have	O
no	O
effect	O
on	O
the	O
pathway	B:C1704259
flux	O
at	O
low	O
concentrations	O
of	O
the	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
substrate	O
palmitoyl	O
-	I:C0030239
CoA	I:C0030239
.	O

Model	O
simulations	O
predicted	O
that	O
MCAD	O
deficiency	I:C0220710
would	O
have	O
no	O
effect	O
on	O
the	O
pathway	O
flux	O
at	O
low	O
concentrations	O
of	O
the	O
mitochondrial	B:C1158366
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
substrate	O
palmitoyl	O
-	I:C0030239
CoA	I:C0030239
.	O

Model	O
simulations	O
predicted	O
that	O
MCAD	O
deficiency	I:C0220710
would	O
have	O
no	O
effect	O
on	O
the	O
pathway	O
flux	O
at	O
low	O
concentrations	O
of	O
the	O
mitochondrial	O
fatty	I:C1158366
-	I:C1158366
acid	I:C1158366
oxidation	I:C1158366
substrate	O
palmitoyl	B:C0030239
-	I:C0030239
CoA	I:C0030239
.	O

However	O
,	O
high	O
concentrations	O
of	O
palmitoyl	B:C0030239
-	I:C0030239
CoA	I:C0030239
would	O
induce	O
a	O
decline	O
in	O
flux	O
and	O
an	O
accumulation	O
of	O
intermediate	O
metabolites	I:C0870883
.	O

However	O
,	O
high	O
concentrations	O
of	O
palmitoyl	O
-	I:C0030239
CoA	I:C0030239
would	O
induce	O
a	O
decline	O
in	O
flux	O
and	O
an	O
accumulation	B:C4055506
of	O
intermediate	O
metabolites	I:C0870883
.	O

However	O
,	O
high	O
concentrations	O
of	O
palmitoyl	O
-	I:C0030239
CoA	I:C0030239
would	O
induce	O
a	O
decline	O
in	O
flux	O
and	O
an	O
accumulation	O
of	O
intermediate	B:C0870883
metabolites	I:C0870883
.	O

We	O
proved	O
computationally	O
that	O
the	O
predicted	O
overload	B:C0030660
behavior	I:C0030660
was	O
due	O
to	O
substrate	O
competition	O
in	O
the	O
pathway	O
.	O

Second	O
,	O
to	O
study	B:C2603343
the	O
clinical	O
relevance	O
of	O
this	O
mechanism	O
,	O
we	O
used	O
patients	O
'	O
metabolite	O
profiles	I:C3853758
and	O
generated	O
a	O
humanized	O
version	I:C0086418
of	O
the	O
computational	O
model	I:C3161035
.	O

Second	O
,	O
to	O
study	O
the	O
clinical	O
relevance	O
of	O
this	O
mechanism	O
,	O
we	O
used	O
patients	O
'	O
metabolite	B:C3853758
profiles	I:C3853758
and	O
generated	O
a	O
humanized	O
version	I:C0086418
of	O
the	O
computational	O
model	I:C3161035
.	O

Second	O
,	O
to	O
study	O
the	O
clinical	O
relevance	O
of	O
this	O
mechanism	O
,	O
we	O
used	O
patients	O
'	O
metabolite	O
profiles	I:C3853758
and	O
generated	O
a	O
humanized	B:C0086418
version	I:C0086418
of	O
the	O
computational	O
model	I:C3161035
.	O

Second	O
,	O
to	O
study	O
the	O
clinical	O
relevance	O
of	O
this	O
mechanism	O
,	O
we	O
used	O
patients	O
'	O
metabolite	O
profiles	I:C3853758
and	O
generated	O
a	O
humanized	O
version	I:C0086418
of	O
the	O
computational	B:C3161035
model	I:C3161035
.	O

While	O
molecular	O
competition	O
did	O
not	O
affect	O
the	O
plasma	B:C0032105
metabolite	O
profiles	I:C3853758
during	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
deficiency	O
,	O
it	O
was	O
a	O
key	O
factor	O
in	O
explaining	O
the	O
characteristic	O
acylcarnitine	O
profiles	O
of	O
multiple	O
acyl	I:C0268596
-	I:C0268596
CoA	I:C0268596
dehydrogenase	I:C0268596
deficient	I:C0268596
patients	O
.	O

While	O
molecular	O
competition	O
did	O
not	O
affect	O
the	O
plasma	O
metabolite	B:C3853758
profiles	I:C3853758
during	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
deficiency	O
,	O
it	O
was	O
a	O
key	O
factor	O
in	O
explaining	O
the	O
characteristic	O
acylcarnitine	O
profiles	O
of	O
multiple	O
acyl	I:C0268596
-	I:C0268596
CoA	I:C0268596
dehydrogenase	I:C0268596
deficient	I:C0268596
patients	O
.	O

While	O
molecular	O
competition	O
did	O
not	O
affect	O
the	O
plasma	O
metabolite	O
profiles	I:C3853758
during	O
medium	B:C0050688
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
deficiency	O
,	O
it	O
was	O
a	O
key	O
factor	O
in	O
explaining	O
the	O
characteristic	O
acylcarnitine	O
profiles	O
of	O
multiple	O
acyl	I:C0268596
-	I:C0268596
CoA	I:C0268596
dehydrogenase	I:C0268596
deficient	I:C0268596
patients	O
.	O

While	O
molecular	O
competition	O
did	O
not	O
affect	O
the	O
plasma	O
metabolite	O
profiles	I:C3853758
during	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
deficiency	B:C0220710
,	O
it	O
was	O
a	O
key	O
factor	O
in	O
explaining	O
the	O
characteristic	O
acylcarnitine	O
profiles	O
of	O
multiple	O
acyl	I:C0268596
-	I:C0268596
CoA	I:C0268596
dehydrogenase	I:C0268596
deficient	I:C0268596
patients	O
.	O

While	O
molecular	O
competition	O
did	O
not	O
affect	O
the	O
plasma	O
metabolite	O
profiles	I:C3853758
during	O
medium	O
-	I:C0050688
chain	I:C0050688
acyl	I:C0050688
-	I:C0050688
CoA	I:C0050688
dehydrogenase	I:C0050688
deficiency	O
,	O
it	O
was	O
a	O
key	O
factor	O
in	O
explaining	O
the	O
characteristic	O
acylcarnitine	O
profiles	O
of	O
multiple	B:C0268596
acyl	I:C0268596
-	I:C0268596
CoA	I:C0268596
dehydrogenase	I:C0268596
deficient	I:C0268596
patients	O
.	O

The	O
patient	O
-	O
specific	O
computational	O
models	O
allowed	O
us	O
to	O
predict	O
the	O
severity	O
of	O
the	O
disease	O
phenotype	O
,	O
providing	O
a	O
proof	O
of	O
principle	O
for	O
the	O
systems	O
medicine	B:C0025118
approach	I:C0025118
.	O

We	O
conclude	O
that	O
substrate	O
competition	O
is	O
at	O
the	O
basis	O
of	O
the	O
physiology	B:C0031843
seen	O
in	O
patients	O
with	O
mFAO	O
disorders	I:C1456270
,	O
a	O
finding	O
that	O
may	O
explain	O
why	O
these	O
patients	O
run	O
a	O
risk	O
of	O
a	O
life	O
-	I:C1968665
threatening	I:C1968665
metabolic	I:C1968665
catastrophe	I:C1968665
.	O

We	O
conclude	O
that	O
substrate	O
competition	O
is	O
at	O
the	O
basis	O
of	O
the	O
physiology	O
seen	O
in	O
patients	O
with	O
mFAO	B:C1456270
disorders	I:C1456270
,	O
a	O
finding	O
that	O
may	O
explain	O
why	O
these	O
patients	O
run	O
a	O
risk	O
of	O
a	O
life	O
-	I:C1968665
threatening	I:C1968665
metabolic	I:C1968665
catastrophe	I:C1968665
.	O

We	O
conclude	O
that	O
substrate	O
competition	O
is	O
at	O
the	O
basis	O
of	O
the	O
physiology	O
seen	O
in	O
patients	O
with	O
mFAO	O
disorders	I:C1456270
,	O
a	O
finding	B:C0243095
that	O
may	O
explain	O
why	O
these	O
patients	O
run	O
a	O
risk	O
of	O
a	O
life	O
-	I:C1968665
threatening	I:C1968665
metabolic	I:C1968665
catastrophe	I:C1968665
.	O

We	O
conclude	O
that	O
substrate	O
competition	O
is	O
at	O
the	O
basis	O
of	O
the	O
physiology	O
seen	O
in	O
patients	O
with	O
mFAO	O
disorders	I:C1456270
,	O
a	O
finding	O
that	O
may	O
explain	O
why	O
these	O
patients	O
run	O
a	O
risk	O
of	O
a	O
life	B:C1968665
-	I:C1968665
threatening	I:C1968665
metabolic	I:C1968665
catastrophe	I:C1968665
.	O

